TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Pro-Brain Natriuretic Peptide Targeted Therapy to Tailor Medical Management of Patients With Congestive Heart Failure Followed in an Outpatient Setting: the ProBNP Outpatient Tailored CHF Therapy (PROTECT) Study
Brief Summary: Levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP) a hormone released from the heart in patients with heart failure (HF) are strongly prognostic of adverse events, such as hospitalization or death from HF. Therapies that are beneficial for HF (such as beta blockers or angiotensin converting enzyme inhibitors) tend to lower levels of NT-proBNP in parallel with improvements in outcomes of patients so treated. Importantly, Nt-proBNP levels may identify a patient at high risk for adverse outcome from their HF, even in periods of apparent stability.

It remains unclear, however, whether treating patients based on their NT-proBNP concentrations would be associated with better outcomes compared to standard HF therapy without measurement of NT-proBNP values.

The goal of the PROTECT study is to evaluate whether treatment of patients with advanced and recently destabilized HF would benefit from NT-proBNP guided HF treatment, compared to standard HF therapy without such 'hormone guided' treatment.


Options:
A: Arm Label: SOC; Type: PLACEBO_COMPARATOR; Interventions: Other: Drug therapy for HF | Arm Label: NT-proBNP arm; Type: ACTIVE_COMPARATOR; Interventions: Other: NT-proBNP guided HF therapy | Intervention Type: OTHER; Name: Drug therapy for HF; Assigned to Arm(s): SOC | Intervention Type: OTHER; Name: NT-proBNP guided HF therapy; Assigned to Arm(s): NT-proBNP arm
B: Arm Label: NT-proBNP guided treatment group; Type: ACTIVE_COMPARATOR; Interventions: Device: NT-proBNP measurements | Arm Label: Clinically guided arm; Type: PLACEBO_COMPARATOR; Interventions: Device: NT-proBNP measurements | Intervention Type: DEVICE; Name: NT-proBNP measurements; Assigned to Arm(s): Clinically guided arm, NT-proBNP guided treatment group
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: OTHER; Interventions: Other: Intervention Care | Intervention Type: OTHER; Name: Intervention Care; Assigned to Arm(s): Intervention
D: Arm Label: Usual Care; Type: EXPERIMENTAL; Interventions: Other: Usual Care | Arm Label: Biomarker-Guided Care; Type: EXPERIMENTAL; Interventions: Device: Biomarker-guided care NT-proBNP | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care | Intervention Type: DEVICE; Name: Biomarker-guided care NT-proBNP; Assigned to Arm(s): Biomarker-Guided Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Pro-Brain Natriuretic Peptide Targeted Therapy to Tailor Medical Management of Patients With Congestive Heart Failure Followed in an Outpatient Setting: the ProBNP Outpatient Tailored CHF Therapy (PROTECT) Study
Brief Summary: Levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP) a hormone released from the heart in patients with heart failure (HF) are strongly prognostic of adverse events, such as hospitalization or death from HF. Therapies that are beneficial for HF (such as beta blockers or angiotensin converting enzyme inhibitors) tend to lower levels of NT-proBNP in parallel with improvements in outcomes of patients so treated. Importantly, Nt-proBNP levels may identify a patient at high risk for adverse outcome from their HF, even in periods of apparent stability.

It remains unclear, however, whether treating patients based on their NT-proBNP concentrations would be associated with better outcomes compared to standard HF therapy without measurement of NT-proBNP values.

The goal of the PROTECT study is to evaluate whether treatment of patients with advanced and recently destabilized HF would benefit from NT-proBNP guided HF treatment, compared to standard HF therapy without such 'hormone guided' treatment.


Options:
A: Arm Label: Usual Care; Type: EXPERIMENTAL; Interventions: Other: Usual Care | Arm Label: Biomarker-Guided Care; Type: EXPERIMENTAL; Interventions: Device: Biomarker-guided care NT-proBNP | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care | Intervention Type: DEVICE; Name: Biomarker-guided care NT-proBNP; Assigned to Arm(s): Biomarker-Guided Care
B: Arm Label: NT-proBNP guided treatment group; Type: ACTIVE_COMPARATOR; Interventions: Device: NT-proBNP measurements | Arm Label: Clinically guided arm; Type: PLACEBO_COMPARATOR; Interventions: Device: NT-proBNP measurements | Intervention Type: DEVICE; Name: NT-proBNP measurements; Assigned to Arm(s): Clinically guided arm, NT-proBNP guided treatment group
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: OTHER; Interventions: Other: Intervention Care | Intervention Type: OTHER; Name: Intervention Care; Assigned to Arm(s): Intervention
D: Arm Label: SOC; Type: PLACEBO_COMPARATOR; Interventions: Other: Drug therapy for HF | Arm Label: NT-proBNP arm; Type: ACTIVE_COMPARATOR; Interventions: Other: NT-proBNP guided HF therapy | Intervention Type: OTHER; Name: Drug therapy for HF; Assigned to Arm(s): SOC | Intervention Type: OTHER; Name: NT-proBNP guided HF therapy; Assigned to Arm(s): NT-proBNP arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment (COLLABORATE)
Brief Summary: We, the researchers, propose to link a clinical pharmacist with an internal medicine or family medicine team to provide pharmaceutical care to all patients assigned to the team. The hypothesis is that through this team based approach, pharmacists will act as a resource for providing pharmacotherapeutic advice during the drug therapy decision making process and promote optimal drug use by identifying and resolving actual and potential drug related problems. This study is designed to test this hypothesis, by assessing the impact of this intervention on evidence based, quality of drug therapy indicators, for patients admitted with heart failure (HF), chronic obstructive pulmonary disease (COPD), community acquired pneumonia (CAP), type 2 diabetes mellitus (T2DM), and stable coronary artery disease (CAD).


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Procedure: New technology - PAML | Intervention Type: PROCEDURE; Name: New technology - PAML; Assigned to Arm(s): Intervention
B: Arm Label: Patients without intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Clinical pharmacy model | Arm Label: Patients with intervention; Type: EXPERIMENTAL; Interventions: Other: Clinical pharmacy model | Intervention Type: OTHER; Name: Clinical pharmacy model; Assigned to Arm(s): Patients with intervention, Patients without intervention
C: Arm Label: Pre-intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Mentored medication reconciliation quality improvement | Intervention Type: OTHER; Name: Mentored medication reconciliation quality improvement; Assigned to Arm(s): Intervention
D: Intervention Type: BEHAVIORAL; Name: Integration of a team based clinical pharmacist; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Optimizing therapeutic treatments; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Optimizing processes of care; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment (COLLABORATE)
Brief Summary: We, the researchers, propose to link a clinical pharmacist with an internal medicine or family medicine team to provide pharmaceutical care to all patients assigned to the team. The hypothesis is that through this team based approach, pharmacists will act as a resource for providing pharmacotherapeutic advice during the drug therapy decision making process and promote optimal drug use by identifying and resolving actual and potential drug related problems. This study is designed to test this hypothesis, by assessing the impact of this intervention on evidence based, quality of drug therapy indicators, for patients admitted with heart failure (HF), chronic obstructive pulmonary disease (COPD), community acquired pneumonia (CAP), type 2 diabetes mellitus (T2DM), and stable coronary artery disease (CAD).


Options:
A: Arm Label: standard care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intensified standard care; Type: OTHER; Interventions: Other: Pharmaceutical Care Service | Intervention Type: OTHER; Name: Pharmaceutical Care Service; Assigned to Arm(s): Intensified standard care
B: Intervention Type: BEHAVIORAL; Name: Integration of a team based clinical pharmacist; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Optimizing therapeutic treatments; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Optimizing processes of care; Assigned to Arm(s): N/A
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Arm 2
D: Arm Label: Comprehensive Geriatric Assessment; Type: EXPERIMENTAL; Interventions: Other: Comprehensive Geriatric Assessment | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive Geriatric Assessment; Assigned to Arm(s): Comprehensive Geriatric Assessment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major Depressive Disorder With Inadequate Response to an Antidepressant Treatment
Brief Summary: To evaluate the efficacy of quetiapine fumarate sustained release (Seroquel SR™) in combination with an antidepressant versus an antidepressant alone in patients with Major Depressive Disorder.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.


Options:
A: Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Paroxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): N/A
B: Arm Label: Lithium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lithium | Arm Label: Quetiapine; Type: EXPERIMENTAL; Interventions: Drug: Quetiapine | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Quetiapine | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): Lithium
C: Arm Label: Duloxetine Hydrochloride (60 mg); Type: EXPERIMENTAL; Interventions: Drug: Duloxetine hydrochloride, Drug: Placebo | Arm Label: Duloxetine Hydrochloride (120 mg); Type: EXPERIMENTAL; Interventions: Drug: Duloxetine hydrochloride, Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine hydrochloride; Assigned to Arm(s): Duloxetine Hydrochloride (120 mg), Duloxetine Hydrochloride (60 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Duloxetine Hydrochloride (120 mg), Duloxetine Hydrochloride (60 mg)
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Amide | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Amide; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Calcium and Vitamin D Malnutrition in Elderly Women
Brief Summary: This study is designed to test whether calcium supplementation alone or calcium plus vitamin D reduces the incidence of fractures, reduces high parathyroid secretory activity, and halts bone loss in a population-based sample of women 55+ years of age.

* A calcium supplement of 1400 mg/d will significantly reduce the cumulative incidence of spine and appendicular fractures over four years for independently living, rural women 55 years of age and older compared to similar women on their usual diets.
* A calcium supplement of 1400 mg/d plus 1100 IU vitamin D/d will significantly reduce the cumulative incidence of spine and appendicular fractures compared to a calcium supplement only.


Options:
A: Arm Label: Cholecalciferol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): Cholecalciferol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: cholecalciferol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol | Arm Label: Ergocalciferol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: ergocalciferol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol; Assigned to Arm(s): cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: ergocalciferol; Assigned to Arm(s): Ergocalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium and vitamin D3 supplementation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium and vitamin D3 supplementation; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Calcium and Vitamin D Malnutrition in Elderly Women
Brief Summary: This study is designed to test whether calcium supplementation alone or calcium plus vitamin D reduces the incidence of fractures, reduces high parathyroid secretory activity, and halts bone loss in a population-based sample of women 55+ years of age.

* A calcium supplement of 1400 mg/d will significantly reduce the cumulative incidence of spine and appendicular fractures over four years for independently living, rural women 55 years of age and older compared to similar women on their usual diets.
* A calcium supplement of 1400 mg/d plus 1100 IU vitamin D/d will significantly reduce the cumulative incidence of spine and appendicular fractures compared to a calcium supplement only.


Options:
A: Intervention Type: DRUG; Name: cholecalciferol; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Physiotherapy; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: MK0822A; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium and vitamin D3 supplementation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium and vitamin D3 supplementation; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3
D: Intervention Type: DRUG; Name: Caltrate® 600 + D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Weight loss intervention; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Calcium and Vitamin D Malnutrition in Elderly Women
Brief Summary: This study is designed to test whether calcium supplementation alone or calcium plus vitamin D reduces the incidence of fractures, reduces high parathyroid secretory activity, and halts bone loss in a population-based sample of women 55+ years of age.

* A calcium supplement of 1400 mg/d will significantly reduce the cumulative incidence of spine and appendicular fractures over four years for independently living, rural women 55 years of age and older compared to similar women on their usual diets.
* A calcium supplement of 1400 mg/d plus 1100 IU vitamin D/d will significantly reduce the cumulative incidence of spine and appendicular fractures compared to a calcium supplement only.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium and vitamin D3 supplementation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium and vitamin D3 supplementation; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tamoxifen | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Raloxifene | Intervention Type: DRUG; Name: Raloxifene; Assigned to Arm(s): Group 2 | Intervention Type: DRUG; Name: Tamoxifen; Assigned to Arm(s): Group 1
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tibolone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tibolone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: raloxifene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Lenalidomide (CC-5013) and Prednisone as a Therapy for Patients With Myelofibrosis (MF)
Brief Summary: The goal of this clinical research study is to learn if lenalidomide in combination with prednisone can help to control myelofibrosis. The safety of lenalidomide and prednisone for the treatment of myelofibrosis will also be studied.


Options:
A: Arm Label: Ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Ruxolitinib
B: Arm Label: Treatment (lenalidomide, prednisone); Type: EXPERIMENTAL; Interventions: Drug: lenalidomide, Drug: prednisone, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): Treatment (lenalidomide, prednisone) | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): Treatment (lenalidomide, prednisone) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Treatment (lenalidomide, prednisone)
C: Arm Label: Lenalidomide + Prednisone; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide, Drug: Prednisone | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Lenalidomide + Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Lenalidomide + Prednisone
D: Arm Label: Ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ruxolitinib, Drug: Placebo | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Placebo, Ruxolitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Effect of Calcium/Vitamin D Supplementation (Caltrate 600+ D) on Body Weight and Fat Loss in Overweight and Obese Individuals on a Weight-Reducing Program.
Brief Summary: The aim of this study was to assess the effect of calcium/vitamin D supplementation (Caltrate 600 +D®) on body weight loss during a weight-reducing program


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: D-cure | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cure; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Caltrate® 600 + D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Weight loss intervention; Assigned to Arm(s): N/A
C: Arm Label: OJ fortified with Ca and VitD; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Orange Juice fortified with Calcium and Vitamin D, Behavioral: Nutritional Counseling | Arm Label: OJ without VitD and Ca; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Orange juice without Ca or VitD, Behavioral: Nutritional Counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Orange Juice fortified with Calcium and Vitamin D; Assigned to Arm(s): OJ fortified with Ca and VitD | Intervention Type: DIETARY_SUPPLEMENT; Name: Orange juice without Ca or VitD; Assigned to Arm(s): OJ without VitD and Ca | Intervention Type: BEHAVIORAL; Name: Nutritional Counseling; Assigned to Arm(s): OJ fortified with Ca and VitD, OJ without VitD and Ca
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium and vitamin D3 supplementation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium and vitamin D3 supplementation; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3

Answer: B